Positive Clinical Data, Marketing Authorizations, and New Appointments Support Growth in Biotech Companies - Research Report on Santarus, VIVUS, Epizyme, Peregrine Pharmaceuticals, and PDL BioPharma

NEW YORK, July 3, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Santarus, Inc. (NASDAQ: SNTS), VIVUS Inc. (NASDAQ: VVUS), Epizyme, Inc. (NASDAQ: EPZM), Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Santarus, Inc. Research Report

On June 25, 2013, Santarus, Inc. (Santarus) and Pharming Group NV announced that new data from a pivotal Phase III clinical study with RUCONEST (recombinant human CC1 esterase inhibitor) was featured in a poster presentation at the European Academy of Allergy and Clinical Immunology (EACCI) and World Allergy Organization (WAO) & Asthma Congress on June 24, 2013 in Milan, Italy. Santarus reported that RUCONEST is a treatment of acute angioedema attacks in patients with hereditary angioedema (HAE). Marc Riedl, M.D., Section Head Department of Clinical Immunology and Allergy, University of California, Los Angeles and Lead Author of the poster, stated, "RUCONEST has the potential to be an important addition to the therapeutic options available for the treatment of acute attacks of HAE based on the encouraging clinical data observed to date." The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/28f6_SNTS]

--

VIVUS Inc. Research Report

On June 26, 2013, VIVUS Inc. (VIVUS) announced that the European Commission (EC) has accepted the implementing decision granting marketing authorization for SPEDRA (avanafil), for the treatment of erectile dysfunction (ED) in the European Union (EU). Peter Tam, President of VIVUS, commented, "SPEDRA represents another significant regulatory approval for VIVUS; it is a tremendous accomplishment both for the Company and for our European team. The unique characteristics of SPEDRA will offer the estimated 20 million European ED patients an important treatment option." Tam continued, "We recently announced positive results from a multicenter, placebo-controlled study, TA-501. In this study, ED patients achieved statistically significant improvement over placebo in the mean proportion of attempts that resulted in erections sufficient for successful intercourse as early as 10 minutes following administration for the 200 mg dose and 12 minutes following administration for the 100 mg dose. We believe the recent study results along with the EU approval significantly enhance the value of the avanafil franchise and will be attractive to potential partners worldwide." The Full Research Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/8deb_VVUS]

--

Epizyme, Inc. Research Report

On June 26, 2013, Epizyme, Inc. (Epizyme) announced the publication of data on its clinical candidate EPZ-5676, a potent and selective small-molecule inhibitor of DOT1L, a histone methyltransferase (HMT). DOT1L is implicated in acute leukemias in which the MLL gene is rearranged (MLL-r). Robert A. Copeland, Ph.D., Executive Vice President and Chief Scientific Officer of Epizyme, said, "This paper provides a clear and comprehensive description of the preclinical characterization of EPZ-5676 that paved the way for this drug becoming the first HMT inhibitor to our knowledge to enter human clinical trials. The work is illustrative of the discovery efforts ongoing at Epizyme that are fueling the clinical development of multiple drugs against the HMT target class." The Full Research Report on Epizyme, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0f2f_EPZM]

--

Peregrine Pharmaceuticals, Inc. Research Report

On June 27, 2013, Peregrine Pharmaceuticals, Inc. (Peregrine) released an update on its bavituximab oncology program, including financing activities focused on advancing its lead program into a pivotal Phase III trial and adapting its clinical development plan in accordance with the recent increased understanding of the immune-stimulatory properties of bavituximab. Joseph Shan, Vice President of Clinical and Regulatory Affairs at Peregrine, commented, "These recent data supporting an immunotherapy mechanism of action for bavituximab opens many new development opportunities including new combinations not previously planned and has created a lot of excitement around the potential of bavituximab in combination with other immunotherapeutic agents." Shan continued, "While exploring these opportunities, our primary focus remains on the initiation of the Phase III trial in second-line NSCLC by year-end based on promising survival data and we are on track to achieve that goal." The Full Research Report on Peregrine Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/df4a_PPHM]

--

PDL BioPharma, Inc. Research Report

On June 25, 2013, PDL BioPharma, Inc. (PDL BioPharma) announced the appointment of Glenn M. Reicin as Senior Advisor to the Company, which became effective on July 1, 2013. PDL BioPharma said that it is focused on acquiring income generating assets to continue increasing shareholder value, and Mr. Reicin will play a key role in bolstering these activities for the Company. John P. McLaughlin, President and CEO of PDL BioPharma, said, "We are pleased to have Glenn join our leadership team and believe that his depth of experience and extensive network in the medical device space will be invaluable as we evaluate opportunities that would bring additional value to PDL." McLaughlin added, "We have completed four significant transactions over the past year and are actively evaluating additional opportunities in order to continue this momentum in the year ahead." The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0666_PDLI]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports